Incretin mimetics provide a pharmacological stimulus to insulin secretion and elicit other GLP-1-receptor-mediated activity as drugs, but are typically introduced at much higher concentrations compared with physiological levels of GLP-1 [65, 66]
This turnover maintains low ETV6 levels, restricts GLUT1 expression, and ensures normal glucose metabolism in endometrial cells
The key difference is cost and accessibilityPlexusDx compounded versions are $189/mo month-to-month, or from $149/mo on the 6-month plan for semaglutide injection, making them accessible without insurance
But the next generationled by retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptorsis showing even more profound benefits
One 55-year-old wound up in the ER with a 30-hour erection after injecting 2 milligrams into his abdomen
doi: 10.2147/DMSO.S320169 314